title: Effect of rebamipide on the colonic barrier in interleukin-10-deficient mice.
abstract: Our aim was to study the effect of a mucosal protective agent, rebamipide, on the colonic barrier and the immune response in colitis-prone interleukin-10-deficient (IL-10-/-) C57BL/6 mice infected with Helicobacter hepaticus. After sacrifice, in all mice, control, or previously infected with H. hepaticus, or previously infected and treated with rebamipide enema, a histological examination of colonic samples was performed, intestinal permeability was studied in Ussing chamber, and mesenteric lymph node proliferation and cytokine secretion were measured. Mice treated with rebamipide presented a reinforcement of the distal colonic epithelial barrier, an increase of mesenteric lymph node cells proliferation, and of IFNgamma and IL-12 secretion. These results indicate that in IL-10-/- mice with mild colitis, rectally administered rebamipide reinforces the distal colonic barrier and has a slight Th1 immuno-stimulatory effect on mesenteric lymph node cells. These properties could be helpful in the management of some inflammatory bowel diseases.
authors.affiliation: INSERM-ERI 10, Université Victor Segalen, Bordeaux, France.
authors.forename: David
authors.initials: D
authors.lastname: Laharie
authors.forename: Sandrine
authors.initials: S
authors.lastname: Ménard
authors.forename: Corinne
authors.initials: C
authors.lastname: Asencio
authors.forename: Teresita
authors.initials: T
authors.lastname: Vidal-Martinez
authors.forename: Anne
authors.initials: A
authors.lastname: Rullier
authors.forename: Frank
authors.initials: F
authors.lastname: Zerbib
authors.forename: Céline
authors.initials: C
authors.lastname: Candalh
authors.forename: Francis
authors.initials: F
authors.lastname: Mégraud
authors.forename: Martine
authors.initials: M
authors.lastname: Heyman
authors.forename: Tamara
authors.initials: T
authors.lastname: Matysiak-Budnik
mesh_terms: D000409:Alanine / Q000031:analogs & derivatives* / Q000494:pharmacology; D000818:Animals; D000897:Anti-Ulcer Agents / Q000494:pharmacology*; D003106:Colon / Q000187:drug effects*; D004195:Disease Models, Animal; D005260:Female; D005434:Flow Cytometry; D016481:Helicobacter Infections / Q000276:immunology*; D044923:Helicobacter hepaticus; D016753:Interleukin-10 / Q000276:immunology; D007413:Intestinal Mucosa / Q000187:drug effects*; D008213:Lymphocyte Activation; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D015363:Quinolones / Q000494:pharmacology*; D013047:Specific Pathogen-Free Organisms; D013601:T-Lymphocytes / Q000276:immunology
chemical_list: D000897:Anti-Ulcer Agents; D015363:Quinolones; D016753:Interleukin-10; C052785:rebamipide; D000409:Alanine